A Phase 1/2 study of ALX148 in combination with venetoclax and azacitidine in patients with acute myeloid leukemia (AML) (ASPEN-05)
MD Anderson Study Status
evorpacept, venetoclax, azacitidine
This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with venetoclax and azacitidine for the treatment of patients with acute myeloid leukemia (AML).
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Acute Myeloid Leukemia, AML, Adult
For general questions about clinical trials:
Due to our response to COVID-19, all blood donations at MD Anderson
Blood Donor Center locations are being held by appointment only.